Loading clinical trials...

COMPLETEDNA

PET Imaging in ALS Patients

Metabotropic Glutamate Receptor 5 (mGluR5) Imaging in Amyotrophic Lateral Sclerosis (ALS) Patients and Healthy Volunteers

NCT02236897•Johns Hopkins University

View on ClinicalTrials.gov

Summary

This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and monitoring progression of ALS, based on a well established basic science pathway, published human autopsy data, preliminary data in ALS mutant mice, and our recently published data using brain PET scans to image the metabotropic glutamate receptor type 5 (mGluR5) in healthy human volunteers.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male or female ALS patients, ranging in age from 18-80.
•Must meet El Escorial Criteria for Probable or Definite ALS.
•Disease duration \>1 year, but \<3 years.
•Weakness in at least two extremities.
•Forced vital capacity less than 80% and greater than 50%.

Exclusion Criteria

•Documented orthopnea or otherwise unable to lie flat in a PET scanner for 90 minutes.
•Presence of pacemakers, aneurysm clips, shrapnel, or other implanted metallic devices that would preclude an MRI scan.
•Absence of sufficient collateral arterial circulation for radial arterial line placement in both wrists.
•Significant abnormalities of hepatic or renal function, or illicit substance use.
•Positive drug screen. (Subjects currently taking prescribed narcotic medication who have a positive drug screen for this medication will not be excluded. Medication history will be obtained during screening).
•Weighs \> 350 lbs.

Locations (1)

Johns Hopkins University

Baltimore, Maryland, United States

Key Dates

Start Date

August 1, 2013

Primary Completion Date

March 1, 2017

Completion Date

March 1, 2017

Last Updated

March 7, 2017

Enrollment

ACTUAL participants

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

PET Scanning

OTHER

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388

Amyotrophic Lateral Sclerosis (ALS)Primary Lateral Sclerosis (PLS)+1 more

View study

RECRUITING

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

NCT07202494

Multiple SclerosisNeuromyelitis Optica Spectrum Disorders+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PET Imaging in ALS Patients

Inclusion Criteria

Exclusion Criteria

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis